Anti-Infectives: World Market, 2nd Edition, Vol III: Antivirals

Table of Contents

Chapter One: Executive Summary

• Introduction
• Scope and Methodology
• Size and Growth of the Market
• Issues and Trends Affecting Market
• Leading Competitors

Chapter Two: Introduction

• Introduction to Viruses
• Examples of Pathogenic Viruses
• Virus Function and Life History
  • Replication in DNA Viruses
  • Replication of RNA Viruses
  • Replication in Retroviruses
• Host Defenses Against Viruses
• Viral Ploys to Invade Host Cells and Circumvent Host Responses
  • Invasion of Host Cells
  • Subversion of the Immune Response
  • Avoidance of Immune Detection and Attack by Killer Cells
• HIV and AIDS
• Demographics and Statistics

Chapter Three: Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors

• Overview
• Description of Products
  • Nucleoside Reverse Transcriptase Inhibitors
    • Abacavir (Ziagen, GlaxoSmithKline)
    • Didanosine (Videx, Bristol-Myers Squibb)
    • Entecavir (Baraclude, Bristol-Myers Squibb)
    • Lamividine (Epivir, GlaxoSmithKline; Zeffix, GlaxoSmithKline)
    • Stavudine (Zerit, Bristol-Myers Squibb)
    • Telbivudine (Tyzeka, Novartis/Idenix Pharmaceuticals)
    • Zalcitabine (Hivid, Roche)
  • Zidovudine (Retrovir, GlaxoSmithKline)
  • Combination Nucleoside Reverse Transcriptase Inhibitors
    • Abacavir and Lamivudine (Epzicom/Kivexa, GlaxoSmithKline)
    • Abacavir sulfate, Lamivudine and Zidovudine (Trizivir, GlaxoSmithKline)
    • Lamivudine and Zidovudine (Combivir, GlaxoSmithKline)
  • Nucleotide Analogue Reverse Transcriptase Inhibitors
    • Adefovir dipivoxil (Hepsera, Gilead Sciences)
    • Tenofovir (Viread, Gilead Sciences)
  • Non-Nucleoside Reverse Transcriptase Inhibitors
    • Efavirenz (Sustiva, Bristol-Myers Squibb Oncology)
    • Delavirdine mesylate (Rescriptor, Agouron Pharmaceuticals)
    • Emtricitabine (Emtriva, Gilead Sciences)
    • Nevirapine (Viramune, Boehringer Ingelheim)
  • Combination Non-Nucleoside Reverse Transcriptase Inhibitors
    • Efavirenz/emtricitaine tenofovir disoproxil fumarate (Atripla, Bristol-Myers Squibb/Gilead Sciences)
    • Tenofovir and emtricitabine (Truvada, Gilead Sciences)
  • DNA Polymerase Inhibitors
    • Acyclovir (Zovirax, GlaxoSmithKline)
    • Cidofovir (Vistide, Gilead Sciences)
    • Famciclovir (Famvir, Novartis)
    • Foscarnet (Foscavir, AstraZeneca)
    • Ganciclovir (Cytovene, Roche)
    • Penciclovir (Denavir, Novartis)
    • Ribavirin (Virazole, ICN Pharmaceuticals)
    • Telbivudine (Tyzeka, Idenix/Novartis)
    • Valacyclovir (Valtrex, GlaxoSmithKline)
    • Valganciclovir (Valcyte, Hoffman-LaRoche)
• Generic Drug Impact and Availability
• Research and Development
• Market Size and Growth
• Competitive Analysis

Chapter Four: Protease Inhibitors

• Overview
• Description of Products
  • Protease Inhibitors
    • Amprenavir (Agenerase, GlaxoSmithKline)
    • Atazanavir (Reyataz, Bristol-Myers Squibb)
    • Darunavir (Prezista, Tibotec Pharmaceuticals)
    • Fosamprenavir (Lexiva, Vertex and GlaxoSmithKline)
    • Indinavir (Crixivan, Merck)
    • Nelfinavir (Viracept, Agouron Pharmaceuticals)
    • Ritonavir (Norvir, Abbott Laboratories)
    • Saquinavir (Fortovase, Roche; Invirase, Roche)
    • Tripanavir (Aptivus, Boehringer Ingelheim)
    • Combination Protease Inhibitors
      • Lopinavir and Ritonavir (Kaletra, Abbott Laboratories)
    • Research and Development
    • Market Size and Growth
    • Competitive Analysis

Chapter Five: Other Antivirals

• Overview
• Description of Products
  • Immune Response Modifiers
  • Imiquimod (Aldara, 3M Pharmaceuticals)
• Immunoglobulin G
  • Cytomegalovirus immune globulin (CytoGam, MedImmune)
• Adamantane Derivatives
  • Rimantadine HCl (Flumadine, Forest Laboratories)
  • Amantadine (Symmetrel, Endo Laboratories)
• Fusion Inhibitors
  • Enfuvirtide (Fuzeon, Trimeris/Roche)
• Interferons
  • Interferon alfacon-1 (Infergen, Amgen)
  • Interferon alpha 2a (Pegasys, Roche)
  • Interferon Alfa-n3 (Alpheron N, Hemispherx Biopharma)
  • Ribavirin + Interferon Alfa 2-a (Pegasys + Copegus, Roche)
  • Ribavirin (Rebetol, Schering-Plough; Rebetron, Schering-Plough; Ribasphere, Three Rivers Pharmaceuticals)
• Neuraminidase Inhibitors
  • Zanamivir (Relenza, GlaxoSmithKline)
  • Oseltamivir phosphate (Tamiflu, Roche)
• Immunizing Agents
  • Hepatitis B immune globulin injection (HepaGam B (Cangene)
  • Respiratory syncytial virus immune globulin (RespiGam, MedImmune)
• Monoclonal Antibodies
  • Palivizumab (Synagis, MedImmune)
• Miscellaneous Antivirals
  • Molixan, (Novelos Therapeutics/Pharma BAM)
• Generic Drug Impact and Availability
• Research and Development
  • Attachment and Fusion Inhibitors
  • Gene Therapies
  • Integrase Inhibitors
  • Maturation Inhibitors
  • Neuraminidase Inhibitors
  • Zinc Finger Inhibitors
  • Antisense Drugs
  • Cytokines
  • Monoclonal Antibodies
  • Other
• Market Size and Growth
• Competitive Analysis

Chapter Six: Issues and Trends Affecting the Antiviral Market

• Introduction
• Antiviral Drug Resistance
• Medicare Part D
• HIV Drug Cost Controversy
• Antiretroviral treatment regimens
• HIV and Women
• Global Surveillance
• Maturation Inhibitor Development
• Biochemical Prevention and Treatment of Viral Infections
• COSTS AND Funding of HIV Treatment
• Access to HIV/AIDS Treatment

Chapter Seven: Antiviral Drugs: Total Market Size and Forecast

• Overview
• Total Market Size and Forecast

Chapter Eight: Corporate Profiles

• Introduction
• Abbott Laboratories
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Gilead Sciences, Inc.
• GlaxoSmithKline
• MedImmune, Inc.
• Merck & Company, Inc.
• Novartis Pharmaceuticals Corporation
• Roche
• Schering-Plough Corporation

APPENDIX: Company Names and Addresses

Table of exhibits

Chapter One: Executive Summary

• Table 1-1:The World Market for Antiviral Drugs 2004-2011

Chapter Two: Introduction

• Table 2-1: Host Cell Receptors
• Table 2-2: Estimated World and U.S. Incidence of Viral Infections
• Figure 2-1: Estimated World and U.S. Incidence of Leading Viral Infections
• Table 2-3: World Population by Selected Geographical Region, 2006-2050
• Figure 2-2: World Population by Selected Geographuhhical Region, 2006-2050
• Table 2-4: Estimated World Population by Age and Geographical Region, 2006
• Table 2-3: Estimated World Population by Age and Geographical Region, 2006

Chapter Three: Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors

• Table 3-1: Currently Available Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
• Table 3-2: Currently Available Combination Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
• Table 3-3: Currently Available Nucleotide Analog Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
• Table 3-4: Currently Available Non-Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
• Table 3-5: Currently Available Combination Non-Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
• Table 3-6: Currently Available DNA Polymerase Inhibitors (Type, Brand, and Manufacturer)
• Table 3-7: New Generic Drug Approvals for Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors, United States, 2005-2006
• Table 3-8: Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors In Development
• Table 3-9: The Market for Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitor 2004-2011
• Figure 3-1: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market 2004-2011
• Table 3-10: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Products Sales by Infection Type, 2006
• Figure 3-2: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Market Share by Infection Type, 2006
• Table 3-11: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Products Sales by Geographic Region, 2006
• Figure 3-3: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Market Share by Geographic Region, 2006
• Table 3-12: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Revenues and Market Share of Leading Suppliers 2006
• Figure 3-4: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Market Share by Leading Suppliers 2006
• Table 3-13: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Projected Revenues and Market Share of Leading Suppliers 2011
• Figure 3-5: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Projected Market Share by Leading Suppliers 2011
• Table 3-14: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Sales of Top Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors 2006
• Figure 3-6: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Market Share of Top Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor , 2006

Chapter Four: Protease Inhibitors

• Table 4-1: Currently Available Protease Inhibitors (Type, Brand, and Manufacturer)
• Table 4-2: Currently Available Combination Protease Inhibitors (Type, Brand, and Manufacturer)
• Table 4-3: Protease Inhibitors in Development
• Table 4-4: The Market for Protease Inhibitors 2004-2011
• Figure 4-1: Protease Inhibitor Market 2004-2011
• Table 4-5: Protease Inhibitor Market Estimated Products Sales by Geographic Region, 2006
• Figure 4-2: Protease Inhibitor Market Market Share by Geographic Region, 2006
• Table 4-6: Protease Inhibitor Market Estimated Revenues and Market Share of Leading Suppliers 2006
• Figure 4-3: Protease Inhibitor Market Estimated Market Share by Leading Suppliers 2006
• Table 4-7: Protease Inhibitor Market Projected Revenues and Market Share of Leading Suppliers 2011
• Figure 4-4: Protease Inhibitor Market Projected Market Share by Leading Suppliers 2011
• Table 4-8: Protease Inhibitor Market Estimated Sales of Top Protease Inhibitors 2006
• Figure 4-5: Protease Inhibitor Market Estimated Market Share of Top Protease Inhibitors, 2006

Chapter Five: Other Antivirals

• Table 5-1: Currently Available Antiviral Immune Response Modifiers (Type, Brand, and Manufacturer)
• Table 5-2: Currently Available Immunoglobulin G Products (Type, Brand, and Manufacturer)
• Table 5-3: Currently Available Adamantane Derivatives (Type, Brand, and Manufacturer)
• Table 5-4: Currently Available Fusion Inhibitors (Type, Brand, and Manufacturer)
• Table 5-5: Currently Available Interferons (Type, Brand, and Manufacturer)
• Table 5-6: Currently Available Neuraminidase Inhibitors (Type, Brand, and Manufacturer)
• Table 5-7: Currently Available Immunizing Agents (Type, Brand, and Manufacturer)
• Table 5-8: Currently Available Monoclonal Antibodies (Type, Brand, and Manufacturer)
• Table 5-9: Miscellaneous Antivirals (Type, Brand, and Manufacturer)
• Table 5-10: New Generic Drug Approvals for Other Antivirals, United States, 2005-2006
• Table 5-11: Other Antivirals in Development
• Table 5-13: The Market for Other Antivirals 2004-2011
• Figure 5-1: Other Antiviral Market 2004-2011
• Table 5-14: Other Antiviral Market Estimated Products Sales by Infection Type, 2006
• Figure 5-2: Other Antiviral Market Market Share by Infection Type, 2006
• Table 5-15: Other Antiviral Market Estimated Products Sales by Geographic Region, 2006
• Figure 5-3: Other Antiviral Market Market Share by Geographic Region, 2006
• Table 5-16: Other Antiviral Market Estimated Revenues and Market Share of Leading Suppliers 2006
• Figure 5-4: Other Antiviral Market Estimated Market Share by Leading Suppliers 2006
• Table 5-17: Other Antiviral Market Projected Revenues and Market Share of Leading Suppliers 2011
• Figure 5-5: Other Antiviral Market Projected Market Share by Leading Suppliers 2011
• Table 5-18: Other Antiviral Market Estimated Sales of Other Antiviral Products 2006
• Figure 5-6: Other Antiviral Market Estimated Market Share of Top Other Antiviral Products, 2006

Chapter Six: Issues and Trends Affecting the Antiviral Market

• Table 6-1 People Living with HIV/AIDS by Region
• Table 6-2: AIDS Resource Needs (USS billion)
• Table 6-3: Access Needs of Adults and Children with HIV by Regions
• Table 6-4: Antiretroviral Access for HIV Infected Individuals by Region

Chapter Seven: Antiviral Drugs: Total Market Size and Forecast

• Table 7-1: The World Market for Antiviral Drugs 2004-2011 Compound Annual Growth Rate
• Figure 7-1: The World Market for Antiviral Drugs 2004-2011
• Table 7-2: Antiviral Drug Market by Type 2004-2011
• Figure 7-2: The World Market for Antiviral Drugs Revenues by Type 2004-2011
• Figure 7-3: The World Market for Antiviral Drugs Revenues by Type 2006 and 2011